BASF said Wednsesday it plans to build a new world-scale plant to produce ibuprofen in Ludwigshafen, Germany.
Ibuprofen is an active pharmaceutical ingredient that is used for treating pain, fever, and inflammation. BASF announced the new plant – the first world-scale ibuprofen plant in Europe – to kick off in 2021.
Dr. Markus Kamieth, Member of the Board of Executive Directors, BASF SE. With this investment, BASF aims to ensure high supply security for its customers and meet growing global demand, Kamieth said.
BASF also said it is expanding its ibuprofen capacities at its production site in Bishop, Texas, to fill current supply gaps for ibuprofen in the market. The US expansion was announced to come onstream in early 2018. The company said it will invest approximately €200 million in both projects.
“BASF will be the only supplier with two ibuprofen assets worldwide. This makes us a highly reliable partner for our customers,” says Kamieth.
Dr. Melanie Maas-Brunner, President of BASF’s Nutrition & Health business, said that both investments show BASF’s strong commitment to the pharmaceutical industry and its pharma solutions business. “They enable us to close supply gaps and efficiently support our customers’ growth plans,” Maas-Brunner said.